---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-022951"
form_type: "8-K"
ticker: null
cik: "0001600847"
company_name: "Gamida Cell Ltd."
filed_at: "2023-03-27T23:59:59+00:00"
generated_at: "2026-06-17T14:59:17.798017+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Gamida Cell FY2022 net loss $79.4M; cuts 17% workforce; cash runway to Q3 2023

## Summary
- Net loss $79.4M in FY2022 ($89.8M in 2021); cash $64.7M at year-end.
- Cuts workforce 17% (~$1.1M severance) to extend cash runway through Q3 2023; discontinues preclinical NK pipeline.
- Omidubicel PDUFA date May 1, 2023; exploring strategic partnerships; plans to launch at 10-15 transplant centers.
- Board chair change: Shawn Cline Tomasello elected chair; two other directors resigned.

## SEC filing metadata
- accession: 0001213900-23-022951
- form_type: 8-K
- cik: 0001600847
- company_name: Gamida Cell Ltd.
- filed_at: 2023-03-27T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 2.05, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1600847/000121390023022951/0001213900-23-022951-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1600847/000121390023022951/ea175734-8k_gamida.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-022951
- JSON: https://secwatch.observer/filing/0001213900-23-022951.json
- Plain text: https://secwatch.observer/filing/0001213900-23-022951.txt

## Key facts
- Earnings Releases
  Gamida Cell Ltd. reported the year ended December 31, 2022 results: net income $79.4 million loss.
  - Period: the year ended December 31, 2022
  - Net income: $79.4 million loss
  - Result: reported results
  source text: Net loss for 2022 was $79.4 million, compared to a net loss of $89.8 million in 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1600847/000121390023022951/0001213900-23-022951-index.htm
- Restructurings & Charges
  Gamida Cell Ltd. announced a restructuring with charges of approximately $1.1 million (approximately 17%).
  - Type: restructuring
  - Charge: approximately $1.1 million
  - Headcount: approximately 17%
  source text: On March 27, 2023, the Company announced a workforce reduction plan (the “ Plan ”), pursuant to which it plans to downsize its current workforce by approximately 17% by the end of the second quarter of 2023. The Plan is being enacted to help extend the Company’s financial resources through the third quarter of 2023, during which time the Company intends to allocate the vast majority of its resources to executing a launch of omidubicel, if approved. Affected employees will be offered separation benefits, including severance payments and temporary healthcare coverage assistance, which severance payments, in Israel, are required under applicable law. Each affected employee’s eligibility for the separation benefits is contingent upon such employee’s execution of a separation agreement that includes a general release of claims against the Company. The Company estimates that the severance and termination-related costs will be approximately $1.1 million and expects to record these charges pri
  evidence_url: https://www.sec.gov/Archives/edgar/data/1600847/000121390023022951/0001213900-23-022951-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.